NetworkNewsBreaks Archive - Page 139 of 2151

TuesdaySep 02, 2025 12:29 pm

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports First-Half 2025 Results and Strengthened Cash Position

Scinai Immunotherapeutics (NASDAQ: SCNI) reported revenues of $773,000 for the six months ended June 30, 2025, up from $284,000 in the prior-year period, reflecting continued growth in its CDMO business. R&D expenses fell to $1.24 million from $2.79 million, while marketing, general and administrative expenses rose to $1.26 million from $1.00 million. Net loss narrowed to $4.13 million compared to $4.48 million a year earlier. Cash and equivalents totaled $989,000 as of June 30, with an additional $4.2 million raised in July and August under the Company’s Standby Equity Purchase Agreement, significantly strengthening liquidity. Scinai advanced its anti-IL-17 NanoAb program,…

TuesdaySep 02, 2025 11:58 am

NetworkNewsBreaks – Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Reports Positive Drill Results from Santa Fe Mine Project in Nevada

Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) announced results from its 2025 Phase One drilling program at the Santa Fe Mine Project in Nevada, completing seven reverse-circulation drill holes totaling 1,210 meters. Highlights include 89.9 meters grading 0.23 g/t Au and 18.3 meters grading 0.73 g/t Au at the York zone, with mineralization open along strike and down-dip, as well as 39.6 meters grading 0.30 g/t Au at the Slab zone, confirming a new target for resource expansion. The results validate Lahontan’s geologic model, expand oxide gold zones, and underscore the growth potential of the recently acquired York claims. Additional drilling…

TuesdaySep 02, 2025 11:43 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present at H.C. Wainwright Global Investment Conference

Calidi Biotherapeutics (NYSE American: CLDI), announced that CEO Eric Poma, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8-10, 2025, at the Lotte New York Palace Hotel in New York. An on-demand presentation will be available starting Sept. 5 at 7 a.m. ET, highlighting Calidi’s RedTail platform, which is designed to protect virus from immune clearance, induce tumor lysis, and deliver therapeutic genetic medicines to metastatic sites through systemic administration. To view the full press release, visit https://nnw.fm/uTZqB About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the…

TuesdaySep 02, 2025 11:00 am

NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8–10, 2025. The on-demand presentation will be available beginning Sept. 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event. To view the full press release, visit https://nnw.fm/vK7sC About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where…

TuesdaySep 02, 2025 10:40 am

NetworkNewsBreaks – Beeline Holdings, Inc. (NASDAQ: BLNE) Reports Strong Q2/25 Results, Targets Profitability in Early 2026

Beeline Holdings (NASDAQ: BLNE), a U.S.-based digital mortgage lender, reported strong results for the second quarter of 2025, highlighting both financial and operational progress. The company posted US$1.7 million in revenue for the quarter ended June 30, representing a 27% increase quarter-over-quarter, while cutting operating costs by 40% to US$5.6 million. Net loss narrowed to US$4.1 million, a 68% improvement from the prior quarter, and adjusted EBITDA also improved. Beeline reduced debt by US$2.7 million during the quarter, bringing its year-to-date repayment to US$6.2 million, and ended Q2 with US$6.3 million in cash. Management reiterated its expectation to reach profitability by…

TuesdaySep 02, 2025 10:00 am

NetworkNewsBreaks – Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) Completes $5.3 Million Acquisition in Missouri

Strawberry Fields REIT (NYSE AMERICAN: STRW) announced it completed the acquisition of a facility in Poplar Bluff, Missouri, comprised of 108 skilled nursing beds and 16 assisted living beds, for $5.3 million. The facility was added to an existing master lease with an affiliate of Reliant Care Group L.L.C., increasing the Company’s annual rents by $530,000 with 3% annual escalators. This transaction marks Strawberry Fields’ 18th facility in Missouri. To view the full press release, visit https://nnw.fm/i6ZGy About Strawberry Fields REIT Strawberry Fields REIT, Inc., is a self-administered real estate investment trust engaged in the ownership, acquisition, development and leasing…

TuesdaySep 02, 2025 9:20 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference

Clene (NASDAQ: CLNN) announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host one-on-one investor meetings. To view the full press release, visit https://nnw.fm/eazOY About Clene Inc. Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8(R)is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and…

TuesdaySep 02, 2025 9:00 am

NetworkNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Expands Global Reach With Launch of SEGG Digital and SEGG Productions

SEGG Media (NASDAQ: SEGG, LTRYW), a sports, entertainment and gaming conglomerate that owns Sports.com, Concerts.com and Lottery.com, announced the launch of two new divisions, SEGG Digital and SEGG Productions, to accelerate international growth, audience engagement and monetization. SEGG Digital, led by Charlie Davis of Jet House and supported by influencer executive Ray Harris, will serve as the company’s marketing arm, deploying data-driven digital and social strategies to scale its flagship brands. SEGG Productions, led by Tamer Hassan, will focus on premium storytelling across music, lifestyle and entertainment, with its first major project, “SAS Unscripted,” hosted by Ant Middleton, already in…

FridayAug 29, 2025 3:22 pm

NetworkNewsBreaks – Lucky Strike Entertainment (NYSE: LUCK) Beats Q4 Estimates as Revenue Trends Improve

Lucky Strike Entertainment (NYSE: LUCK), one of the world’s premier location-based entertainment platforms with more than 360 sites across North America, reported fiscal Q4 2025 revenue of $318 million, above Noble Capital Markets’ $292 million estimate, and adjusted EBITDA of $88.7 million versus the $83 million forecast. Same-store revenue declined 4.1% for the quarter, but showed steady sequential improvement from down 6% in April to flat in June, with July turning positive at more than 1% growth. Analysts at Noble Capital Markets noted the results cap a transitional year marked by strengthening revenue trends. To view the full report, visit…

FridayAug 29, 2025 3:09 pm

NetworkNewsBreaks – Zevra Therapeutics, Inc. (NASDAQGS: ZVRA) to Present New MIPLYFFA Data at ICIEM, Poster Earns Best Poster Award

Zevra Therapeutics (NASDAQGS: ZVRA), a commercial-stage company focused on therapies for rare diseases, announced that four posters on MIPLYFFA (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), held Sept. 2-6, 2025, in Kyoto, Japan. MIPLYFFA, approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC), will be highlighted in a Best Poster award-winning presentation (#BP-19) detailing its unique mechanism of action targeting NPC pathophysiology. Additional presentations will feature positive new data from a pediatric substudy in patients younger than two years old and a prespecified efficacy analysis in patients on miglustat…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks